A high drug failure rate is more than just a pattern recognition problem. Here's how we can address some of the root causes.

The ability to probe the smallest building blocks of matter has long fascinated scientists, fueling advancements in medicine, ...

Scientists develop groundbreaking dual-action drug RI-AG03 that targets toxic tau proteins in Alzheimer's disease, showing ...

Andrew Pierce, senior executive at French biotech Owkin, on how artificial intelligence can make the drug development process ...

There is growing enthusiasm about China’s potential to speed up drug development with AI. And companies outside the country ...

A groundbreaking cannabinoid-based antimicrobial, Silvanex, fights drug-resistant infections with a synergy of silver, CBC ...

Hundreds of thousands of doses of moxidectin – which treats a disease caused by a parasitic worm – are being given to ...

Emily Field, head of European pharmaceuticals research at Barclays, weighs in on rising competition in the global obesity ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...

Conduit and Sarborg complete all milestones of Phase I of their AI-driven drug development collaboration, and commence transitioning to Phase II, ...

In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI discusses ...